A postmarketing, open-label study to evaluate the tolerability and effectiveness of replacing standard-formulation doxazosin with doxazosin in the gastrointestinal therapeutic system formulation in adult patients with hypertension

Clinical Therapeutics

Volumn 24, Issue 5, 2002, Pages 786-797

  Anegón, Maria ^a   Esteban, Jesus ^a   Jiménez García, Rodrigo ^a   Sanz De Burgoa, Veronica ^b   Martínez, Javier ^b   Gil De Miguel, Angel ^a,b  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b PFIZER INC   (United States)

Author keywords

Arterial hypertension (AHT); Doxazosin; Gastrointestinal therapeutic system (GITS); Tolerability

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ANTIHYPERTENSIVE AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FEMALE; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; POSTMARKETING SURVEILLANCE; SLOW RELEASE FORMULATION; SOMNOLENCE; STOMACH PAIN; SYNCOPE; SYSTOLIC BLOOD PRESSURE; VOMITING; BLOOD PRESSURE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECT; DRUG TOLERANCE; METHODOLOGY; MIDDLE AGED;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; DOXAZOSIN; DRUG TOLERANCE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 0036015028     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)85152-9     Document Type: Article

References (25)

1. Hypertension-related mortality and arterial pressure
2. Reducción del riesgo en la hipertensión arterial asociada a factores de riesgo cardiovascular. Proyecto HYDRA
3. Evolución del control de la hipertensión arterial en España. Resultados del estudio controlpres 98
4. Doxazosin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild to moderate hypertension
5. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia
6. Effects of age, gender and food on the pharmacokinetics of a controlled-release doxazosin gastrointestinal therapeutic system
7. The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V)
8. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC VI)
9. 1993 Guidelines for the management of mild hypertension: Memorandum from a World Health Organization/International Society of Hypertension meeting
10. British Hypertension Society guidelines for hypertension management 1999: Summary
11. 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension
12. Doxazosin: An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia
13. Alpha-blocker therapy of hypertension: An unfulfilled promise
14. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation
15. Treatment of mild hypertension study: Final results
16. Efectividad de doxazosina en pacientes hipertensos con hiperplasia prostática benigna y prostatismo asociado
17. Doxazosin: A study in a cohort of patients with hypertension in general practice - An interim report
18. Preliminary results of Norwegian doxazosin postmarketing surveillance study: A twelve-week experience
19. Tratamiento con doxazosina en monoterapia en pacientes hipertensos con diabetes no insulino dependiente asociada
20. Tratamiento combinado con doxazosina en pacientes hipertensos no controlados con monoterapia
21. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension
22. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia
23. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension